.
5%
15%
25%
35%
Reduction of systolic BP (4 mmHg)
Reduction of HbA1C (0.9%)
Reduction of LDL cholesterol (38.6 mg/dL)
All of the above
6-6.5%
6.5-7%
7-7.5%
7.5-8%
Patients with DM but no CHD experience a higher rate of MI as patients without DM but with CHD
Patients with DM but no CHD experience a lower rate of MI as patients without DM but with CHD
Patients with DM but no CHD experience a similar rate of MI as patients without DM but with CHD
Diabetes is diagnosed if HbA1c ≥ 6% in at least 2 measurements
Diabetes is diagnosed if HbA1c ≥ 6.5% in at least 2 measurements
Diabetes is diagnosed if HbA1c ≥ 7% in at least 2 measurements
Diabetes is diagnosed if HbA1c ≥ 7.5% in at least 2 measurements
Metformin
Gliptins
SGLT2 inhibitor
GLP-1 agonists
FPG ≥ 110 mg/dL
HbA1C ≥ 6.5%
2-h PG ≥ 200 mg/dL
Classical symptoms of hyperglycemia and random PG ≥ 200 mg/dL
DPP-4 inhibitors and GLP-1 agonists
GLP-1 agonists and SGLT2 inhibitors
SGLT2 inhibitors and TZDs
DPP-4 inhibitors and TZDs
Metformin and insulin
DPP4 inhibitors and Metformin
SGLT2 inhibitors and GLP-1 agonists
SGLT2 inhibitors and long acting GLP-1 agonists
GLP1 agonists and SGLT2i
α-glucosidase inhibitors and Linagliptin
Linagliptin and Dapagliflozin
TZDs and Saxagliptin
Liraglutide
Empagliflozin
Metformin
Dapagliflozin
Dapagliflozin
Linagliptin
Glimepride
2&3
All of the above
Empagliflozin
Dapagliflozin
Sitagliptin
Insulin
Metformin
Glibenclamide
Linagliptin
Empagliflozin
First-degree relative with diabetes
Hypertension (≥140/90 mmHg or therapy for hypertension)
Active smoker
Women with polycystic ovary syndrome
Statins
Antihypertensives
Aspirin
Empagliflozin
Liraglutide
Saxagliptin
SGLT2i
GLP-1 agonists
Rosiglitazone
Rosiglitazone
Dapagliflozin
Saxagliptin
Acarbose
Sulfonylureas
Meglitinides
Gliptins
A and b
A and c
Saxagliptin
Rosiglitazone
Repaglinide
Exenatide